Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2021
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic OpportunitiesMaxwell R Lloyd, Laura M Spring, Aditya Bardia, et al.
JCO Oncology Practice|July 7, 2026
SERD Wars: Clinical Integration of Emerging Endocrine-Directed and Precision Therapies in Breast CancerMaxwell R Lloyd, Rebecca A Shatsky, Neil Love, et al.
Cancer|June 29, 2022
Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancerNathan W Watson, Seth A Wander, Joseph J Shatzel, et al.
Cell Reports|March 7, 2019
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor ResistanceLiam Cornell, Seth A Wander, Tanvi Visal, et al.
Nature Reviews. Clinical Oncology|August 23, 2024
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancerMaxwell R Lloyd, Komal Jhaveri, Kevin Kalinsky, et al.
Cancer Cell|May 21, 2026
Reimagining HER2 therapy: Bridging oncogene addiction and immune modulationLuke Tillman, Lajos Pusztai, Seth A Wander, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging roleMaxwell R Lloyd, Seth A Wander, Erika Hamilton, et al.
Cancer Cell|February 10, 2026
Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancerJuan Luis Gomez Marti, Elena Michaels, Azadeh Nasrazadani, et al.
Breast Cancer Research and Treatment|July 7, 2025
A 40-year-old woman with early-stage triple-negative breast cancer and a retinal lesionShivahamy Maheswaran, Arielle J Medford, Tomasz P Stryjewski, et al.
Lancet (London, England)|March 9, 2020
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and futureLaura M Spring, Seth A Wander, Fabrice Andre, et al.
Pageof 8